美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

250.40

-17.9900-6.70%

盤後：251.981.58+0.63%19:59 EDT

成交量：32.56萬

成交額：8,161.00萬

市值：4.94億

市盈率：- -

高：267.90

開：266.14

低：243.24

收：268.39

52周最高：341.93

52周最低：76.29

股本：197.45萬

流通股本：197.45萬

量比：1.30

換手率：16.49%

股息：1.02

股息率：0.41%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

ETF&股票定投概念-0.49%

資金流向

資金流入：

資金流出：

新聞資訊

醫療健康板塊市場動態綜述

醫療保健板塊動態匯總：市場快訊

美國人口普查局：2025年，92.1%的美國人在部分時段或全年享有醫療保險。

港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/LABU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":250.4,"timestamp":1789502400000,"preClose":268.39,"halted":0,"volume":325606,"hourTrading":{"tag":"盘后","latestPrice":251.98,"preClose":250.4,"latestTime":"19:59 EDT","volume":8108,"amount":2036460.6035,"timestamp":1789516773600,"change":1.58,"changeRate":0.00631,"amplitude":0.00631},"delay":0,"changeRate":-0.0670293230001117,"floatShares":1974486,"shares":1974486,"eps":0,"marketStatus":"已收盤","change":-17.99,"latestTime":"09-15 16:00:00 EDT","open":266.14,"high":267.9,"low":243.2444,"amount":81609965.98544,"amplitude":0.091865,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":268.39,"sharesOutstanding":3074486,"nav":268.659,"aum":530464172.89,"dividendRate":0.00407,"bidAskSpread":0.003539,"preHourTrading":{"tag":"盘前","latestPrice":267.7,"preClose":268.39,"latestTime":"09:25 EDT","volume":476,"amount":126913.024,"timestamp":1789478754552,"change":-0.69,"changeRate":-0.002571,"amplitude":0.027721},"postHourTrading":{"tag":"盘后","latestPrice":251.98,"preClose":250.4,"latestTime":"19:59 EDT","volume":8108,"amount":2036460.6035,"timestamp":1789516773600,"change":1.58,"changeRate":0.00631,"amplitude":0.00631},"volumeRatio":1.297319,"impliedVol":0.9273,"impliedVolPercentile":0.5657},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1974486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.297319,"shares":1974486,"dividePrice":1.0191,"high":267.9,"amplitude":0.091865,"preClose":268.39,"low":243.2444,"week52Low":76.29,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":250.4,"eps":0,"divideRate":0.00407,"volume":325606,"delay":0,"ttmEps":0,"open":266.14,"prevYearClose":159.39,"prevWeekClose":261.3,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":293.07,"twentyDayClose":287.3,"sixtyDayClose":206.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142651526","title":"醫療健康板塊市場動態綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1142651526","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142651526?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 04:52","pubTimestamp":1789505567,"startTime":"0","endTime":"0","summary":"医疗健康领域最新市场快讯，涵盖多家药企与医疗器械公司的股价波动与分析师观点。市场表现方面，阿斯利康股价上涨2.25%，报163.78美元。该股目前下跌1.9%，报113.20瑞郎。杰富瑞对Immutep转持看多立场，分析师David Stanton认为这家生物技术公司的主要候选药物有了更清晰的发展路径。Stanton将评级从持有上调至买入，对该澳大利亚公司关于肺癌研究提前终止似乎与临床因素或试验执行无关的更新感到鼓舞。杰富瑞将目标价翻倍至8澳分。该股持平于4.7澳分。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","LABU","XLV","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146582906","title":"醫療保健板塊動態匯總：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1146582906","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146582906?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 00:22","pubTimestamp":1789489368,"startTime":"0","endTime":"0","summary":"贝伦贝格的分析师在最新研报中指出，阿斯利康拥有强劲且多元化的产品组合，其研发管线蕴藏着巨大的潜力。他们认为，这家制药巨头当前管线项目有望实现13%的研发投资回报率。尽管2026年一些备受期待的研究结果遭遇挫折，但这些失利已被其他积极成果所抵消，这恰恰凸显了多元化投资组合的重要性。截至发稿，阿斯利康股价上涨2.25%，报163.78美元。该股持平于4.7澳分。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4581","BK4588","XBI","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628604","title":"美國人口普查局：2025年，92.1%的美國人在部分時段或全年享有醫療保險。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628604","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667628604?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 22:09","pubTimestamp":1789481360,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["XBI","LABU","XLV","BK4588","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667619385","title":"港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667619385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667619385?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:36","pubTimestamp":1789450580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B午后飙升逾17%。消息面上，礼邦医药近日宣布，AP308用于治疗IgA肾病的新药临床试验申请近日获美国食品药品监督管理局批准。公司计划于近期启动AP308的首次人体临床试验。AP308的IND获批标志着这一首创新药由临床前研究迈入临床开发阶段。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09637","BK1574","09939","159938","VXUS","BK1191","BK1515","BK4585","KCAI","LABU","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":50,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LABU\",params:#limit:6,delay:false,,,undefined,":[{"market":"US","name":"ETF&股票定投概念","id":"package_us_concept_etf&gpdt","bkCode":"BK4585","changeRate":-0.00489},{"market":"US","name":"碎股","id":"package_us_concept_sg","bkCode":"BK4588","changeRate":-0.00491}]}}